EFFECTS OF KETANSERIN ON LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS

被引：13

作者：

COBO, C ^{[1
]}

ALCOCER, L ^{[1
]}

CHAVEZ, A ^{[1
]}

机构：

[1] HOSP GEN MEXICO CITY,MEXICO CITY,MEXICO

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 1990年 / 4卷

关键词：

blood pressure; ketanserin; left ventricular hypertrophy;

D O I：

10.1007/BF00053431

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ketanserin, a serotonergic S2-receptor antagonist, was used in a prospective study in nine hypertensive patients with ECG criteria of left ventricular hypertrophy (LVH). Echocardiographic measurement with M mode was made after 1 month of placebo, and after 3, 6, and 12 months of ketanserin treatment as monotherapy at a mean dose of 31 mg bid. Ketanserin treatment decreased mean left ventricular mass by 9.3% at 3 months (not significant), by 15.3% at 6 months (p < 0.008), and by 26.2% at 12 months (p < 0.02), with a tendency towards improvement in left ventricular ejection fraction, which was not statistically significant. The study showed a sustained effect upon regression of LVH in hypertensives, with preservation of left ventricular function. © 1990 Kluwer Academic Publishers.

引用

页码：73 / 76

页数：4

共 14 条

[1] Frohlich E.D., Cardiac hypertrophy in hypertension, N Engl J Med, 317, pp. 831-833, (1987)
[2] Frohlich E.D., Left ventricular hypertrophy as a risk factor, Cardiology Clinics, Vol. 4, pp. 137-144, (1986)
[3] McLenachan J.M., Henderson E., Morris K.I., Et al., Ventricular arrhythmias in hypertensive left ventricular hypertrophy, N Engl J Med, 317, pp. 787-792, (1987)
[4] Alcocer L., Aspe J., Arce E., Left ventricular hypertrophy in hypertension. Considerations regarding its characteristics and its regression, Arterial Hypertension, pp. 240-243, (1980)
[5] Dunn F.G., Chandraratna P., De Carcalho J.G.R., Et al., Pathophysiologic assessment of hypertensive heart disease with echocardiography, Am J Cardiol, 39, pp. 789-795, (1977)
[6] Alcocer L., Aspe J., The effect of antihypertensive treatment with methyldopa on left ventricular mass, Royal Society of Medicine, International Congress and Symposium Series, 9, pp. 93-97, (1979)
[7] Vanhoutte P., Amery A., Birkenhager W., Et al., Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin, Hypertension, 11, pp. 111-133, (1988)
[8] Fisch C.H., Electrocardiography and vectocardiography, Heart Disease, pp. 195-257, (1984)
[9] Kannel W.B., Gordon T., Offutt D., Left ventricular hypertrophy by electrocardiogram: Prevalence, incidence and mortality in the Framingham study, Ann Intern Med, 71, pp. 89-105, (1969)
[10] Hedner T., Anderson O., Winther K., Et al., Are there reasons to believe that the antihypertensive effects of serotonin (S2) antagonists are age-related?, J Cardiovasc Pharmacol, 12, pp. S132-S140, (1988)

← 1 2 →